Literature DB >> 27696701

The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.

P A Kyrle1,2, M Kammer3, L Eischer1, A Weltermann4, E Minar5, M Hirschl6, G Heinze3, S Eichinger1,2.   

Abstract

Essentials Long-term recurrence risk of venous thromboembolism (VTE) is uncertain. We performed a prospective cohort study of 839 patients with first unprovoked VTE. VTE recurrence risk is high, particularly in men with proximal thrombosis or pulmonary embolism. Sex and VTE site determine the recurrence risk and should be considered for patient counseling.
SUMMARY: Background The long-term recurrence risk (ltRR) of venous thromboembolism (VTE) is uncertain. Objective To assess the ltRR of patients with first unprovoked VTE. Patients/methods Patients were classified into three categories: distal deep vein thrombosis (DVT), proximal DVT or pulmonary embolism (PE), that is, PE associated with DVT or isolated PE. Patients with major thrombophilia or antithrombotic therapy were excluded. The endpoint was recurrent symptomatic VTE. Results A total of 839 patients were followed for a median of 7.7 years. VTE recurred in 263 patients (31%). After 10 and 20 years, the cumulative ltRR was 32% (95% confidence interval [CI], 29-36) and 44% (95% CI, 38-49) with 3.9 (95% CI, 3.3-4.6) and 3.3 (95% CI, 2.7-4.0) events per 100 patient-years, respectively. The adjusted hazard ratio was 2.1 (95% CI, 1.4-3.2) and 2.1 (95% CI, 1.4-3.2) for patients with proximal DVT or PE compared with patients with distal DVT and was 2.1 (95% CI, 1.6-2.9) for men compared with women. At 10 years, 4.7 (95% CI, 3.8-5.8) events per 100 patient-years occurred in men with proximal DVT or PE, 2.4 (95% CI, 1.2-4.4) in men with distal DVT, 1.9 (95% CI, 1.2-2.8) in women with proximal DVT or PE and 0.9 (95% CI, 0.2-1.9) in women with distal DVT. Conclusion The ltRR of patients with first unprovoked VTE is high and dependent upon sex and VTE site.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  deep vein thrombosis; observational study; pulmonary embolism; relapse; venous thromboembolism

Mesh:

Substances:

Year:  2016        PMID: 27696701     DOI: 10.1111/jth.13524

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  17 in total

Review 1.  Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Authors:  Marc Alan Rodger; Gregoire Le Gal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.

Authors:  Davide Imberti; Fulvio Pomero; Daniela Mastroiacovo
Journal:  Blood Transfus       Date:  2019-04-30       Impact factor: 3.443

Review 3.  Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Authors:  Marc Alan Rodger; Gregoire Le Gal
Journal:  Blood Adv       Date:  2018-11-13

4.  Recurrence rate of venous thromboembolic events in granulomatosis with polyangiitis.

Authors:  Alana Nevares; Kinanah Yaseen; Hiromichi Tamaki; James Bena; William Messner; Alexandra Villa-Forte
Journal:  Rheumatol Adv Pract       Date:  2022-07-01

5.  Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer.

Authors:  F Dentali; S Barco; S Pegoraro; M N D Di Minno; D Mastroiacovo; F Pomero; C Lodigiani; F Bagna; M Sartori; G Barillari; N Mumoli; M Napolitano; S M Passamonti; R Benedetti; W Ageno; M Di Nisio
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

6.  Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis.

Authors:  Faizan Khan; Alvi Rahman; Marc Carrier; Clive Kearon; Sam Schulman; Francis Couturaud; Paolo Prandoni; Sabine Eichinger; Cecilia Becattini; Giancarlo Agnelli; Harry R Büller; Timothy A Brighton; Gualtiero Palareti; Laurent Pinede; Elham Sabri; Brian Hutton; George A Wells; Marc A Rodger
Journal:  BMJ Open       Date:  2017-09-21       Impact factor: 2.692

7.  Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases.

Authors:  Valerio De Stefano; Elena Rossi; Alessandra Carobbio; Arianna Ghirardi; Silvia Betti; Guido Finazzi; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-11-12       Impact factor: 11.037

8.  Elevated leptin and decreased adiponectin independently predict the post-thrombotic syndrome in obese and non-obese patients.

Authors:  Sandra Mrozinska; Joanna Cieslik; Elżbieta Broniatowska; Anetta Undas
Journal:  Sci Rep       Date:  2018-05-02       Impact factor: 4.379

9.  Deep Venous Thrombosis Recurrence and Its Predictors at Selected Tertiary Hospitals in Ethiopia: A Prospective Cohort Study.

Authors:  Abera Mulatu; Tsegaye Melaku; Legese Chelkeba
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

10.  Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction.

Authors:  Michael Nagler; Hugo Ten Cate; Martin H Prins; Arina J Ten Cate-Hoek
Journal:  Res Pract Thromb Haemost       Date:  2018-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.